Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

Martin V Nguyen; Lydia Loof; Gerald S Falchook

doi:10.4103/JIPO.JIPO_2_20

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

J Immunother Precis Oncol. 2020 Feb 5;3(1):16-22. doi: 10.4103/JIPO.JIPO_2_20. eCollection 2020 Feb.

Authors

Martin V Nguyen¹, Lydia Loof¹, Gerald S Falchook¹

Affiliation

¹ Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.

Abstract

The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are associated with some solid tumor cancers, including nuclear protein in testis midline carcinoma. BET protein has a role in carcinogenesis and in the regulation of the cell cycle. A number of BET inhibitors have entered clinical trials. This review discusses the results of BET inhibitor clinical trials in solid tumor cancers.

Keywords: Bromodomain and extraterminal domain; bromodomain and extraterminal inhibitor; cancer; clinical trial; review.

Publication types

Review

Grants and funding

Financial support and sponsorship: The authors disclosed no funding related to this article.